KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Biogen (BIIB) Shares Outstanding (Weighted Average) (2016 - 2026)

Biogen has reported Shares Outstanding (Weighted Average) over the past 18 years, most recently at $147.2 million for Q1 2026.

  • For Q1 2026, Shares Outstanding (Weighted Average) rose 0.75% year-over-year to $147.2 million; the TTM value through Mar 2026 reached $147.2 million, up 0.75%, while the annual FY2025 figure was $146.5 million, 0.62% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q1 2026 was $147.2 million at Biogen, roughly flat from $146.5 million in the prior quarter.
  • Over five years, Shares Outstanding (Weighted Average) peaked at $147.2 million in Q1 2026 and troughed at $144.4 million in Q1 2023.
  • A 5-year average of $145.8 million and a median of $145.6 million in 2024 define the central range for Shares Outstanding (Weighted Average).
  • Biggest five-year swings in Shares Outstanding (Weighted Average): decreased 3.16% in 2022 and later rose 0.76% in 2025.
  • Year by year, Shares Outstanding (Weighted Average) stood at $145.3 million in 2022, then dropped by 0.41% to $144.7 million in 2023, then grew by 0.62% to $145.6 million in 2024, then rose by 0.62% to $146.5 million in 2025, then rose by 0.48% to $147.2 million in 2026.
  • Business Quant data shows Shares Outstanding (Weighted Average) for BIIB at $147.2 million in Q1 2026, $146.5 million in Q4 2025, and $146.6 million in Q3 2025.